CLINICAL TRIALS PROFILE FOR PEDIARIX

All Clinical Trials for PEDIARIX

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00133445 ↗	Pentavalent DTaP-Hep B-IPV	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2	2005-12-01	The purpose of this study is to evaluate the safety of administering a combination vaccine (DTaP-HepB-IPV; Pediarix™) to infants at birth, 2 and 6 months compared to the administration of a HepB vaccine at birth and the same combination vaccine at 2, 4, and 6 months of age. Additionally, researchers will assess the body's antibody response (proteins produced by the body's immune system that help fight infections) following each vaccine dose. The study will enroll 5 healthy newborns, ages 0-5 days. Participants will be involved in study related procedures for up to 288 days, including blood sample collection and 5 study visits.

Clinical Trial Conditions for PEDIARIX

Condition Name

Condition Name for PEDIARIX
Intervention	Trials
Diphtheria	1
Hepatitis B	1
Pertussis	1
Poliomyelitis	1

Condition MeSH

Condition MeSH for PEDIARIX
Intervention	Trials
Poliomyelitis	1
Hepatitis B	1
Diphtheria	1

Clinical Trial Locations for PEDIARIX

Trials by Country

Trials by Country for PEDIARIX
Location	Trials
United States	1

Trials by US State

Trials by US State for PEDIARIX
Location	Trials
California	1

Clinical Trial Progress for PEDIARIX

Clinical Trial Phase

Clinical Trial Phase for PEDIARIX
Clinical Trial Phase	Trials
Phase 2	1

Clinical Trial Status

Clinical Trial Status for PEDIARIX
Clinical Trial Phase	Trials
Completed	1

Clinical Trial Sponsors for PEDIARIX

Sponsor Name

Sponsor Name for PEDIARIX
Sponsor	Trials
National Institute of Allergy and Infectious Diseases (NIAID)	1

Sponsor Type

Sponsor Type for PEDIARIX
Sponsor	Trials
NIH	1